Literature DB >> 21132008

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines.

H Zhang1, S Guttikonda, L Roberts, T Uziel, D Semizarov, S W Elmore, J D Leverson, L T Lam.   

Abstract

Non-small-cell lung cancer (NSCLC) is the most deadly type of cancer in the United States and worldwide. Although new therapy is available, the survival rate of NSCLC patients remains low. One hallmark of cancer cells is defects in the apoptotic cell death program. In this study, we investigate the role of B-cell lymphoma 2 (Bcl-2) family members Bcl-2, Bcl-x(L) and Mcl-1, known to regulate cell survival and death, in a panel of fourteen NSCLC cell lines. NSCLC cell lines express high levels of Mcl-1 and Bcl-x(L), but not Bcl-2. Silencing the expression of Mcl-1 with small interfering RNA (siRNA) oligonucleotides potently killed a subgroup of NSCLC cell lines. In contrast, Bcl-x(L) siRNA had no effect in these lines unless Mcl-1 siRNA was also introduced. Interestingly, high MCL1 to BCL-xl messenger RNA determines whether the cells depend on Mcl-1 for survival. We further investigated the role of Mcl-1 in NSCLC cells using a Mcl-1-dependent cell line, H23. The expression of a complementary DNA containing only the coding region of MCL1 rescued H23 cells from the toxicity of a 3' untranslated region (UTR) targeting Mcl-1 siRNA but not a siRNA targeting the coding region of MCL1. Furthermore, we show that Mcl-1 sequesters the BH3-only protein Noxa and Bim and the apoptotic effector Bak. Not surprisingly, Noxa, Bim, or Bak knockdown partially rescued H23 cells from toxicity mediated by Mcl-1 siRNA to different degrees. Collectively, our results indicate that targeting Mcl-1 may improve therapy for a subset of NSCLC patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132008     DOI: 10.1038/onc.2010.559

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  66 in total

1.  Caveolin-1 regulates Mcl-1 stability and anoikis in lung carcinoma cells.

Authors:  Preedakorn Chunhacha; Varisa Pongrakhananon; Yon Rojanasakul; Pithi Chanvorachote
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-25       Impact factor: 4.249

2.  A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Authors:  S Thrane; A M Pedersen; M B H Thomsen; T Kirkegaard; B B Rasmussen; A K Duun-Henriksen; A V Lænkholm; M Bak; A E Lykkesfeldt; C W Yde
Journal:  Oncogene       Date:  2014-11-03       Impact factor: 9.867

3.  Down-regulation of miR-320 associated with cancer progression and cell apoptosis via targeting Mcl-1 in cervical cancer.

Authors:  Ting Zhang; Ping Zou; Tiejun Wang; Jingying Xiang; Jing Cheng; Daozhen Chen; Jianwei Zhou
Journal:  Tumour Biol       Date:  2016-01-11

Review 4.  Biomarkers of therapeutic response to BCL2 antagonists in cancer.

Authors:  Lloyd T Lam; Haichao Zhang; Brenda Chyla
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

Review 5.  The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

Authors:  Aaron N Hata; Jeffrey A Engelman; Anthony C Faber
Journal:  Cancer Discov       Date:  2015-04-20       Impact factor: 39.397

6.  Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancer.

Authors:  Sarah A Wieczorek; Frank Breitenbuecher; Aashish Soni; Katja Paul-Konietzko; Sophie Ziegler; Ali Sak; George Iliakis; Martin Schuler
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553

7.  Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.

Authors:  Anders Friberg; Dominico Vigil; Bin Zhao; R Nathan Daniels; Jason P Burke; Pedro M Garcia-Barrantes; DeMarco Camper; Brian A Chauder; Taekyu Lee; Edward T Olejniczak; Stephen W Fesik
Journal:  J Med Chem       Date:  2012-12-17       Impact factor: 7.446

8.  Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.

Authors:  Timothy G Whitsett; Ian T Mathews; Michael H Cardone; Ryan J Lena; William E Pierceall; Michael Bittner; Chao Sima; Janine LoBello; Glen J Weiss; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2014-01-27       Impact factor: 5.852

9.  Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells.

Authors:  Yang Gao; Kazunori Koide
Journal:  ACS Chem Biol       Date:  2013-03-13       Impact factor: 5.100

10.  Roles of caveolin-1 on anoikis resistance in non small cell lung cancer.

Authors:  Preedakorn Chunhacha; Pithi Chanvorachote
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.